Mapping the regulatory landscape that governs your promotion

In July 2012 GSK agreed to pay $3 billion to resolve US criminal and civil charges, at the time the largest health care fraud settlement in the country. Almost none of it turned on whether the molecules worked. It turned on promotion: Paxil pushed for adolescents, Wellbutrin pushed for weight loss and sexual dysfunction, neither use approved by the FDA, alongside failures to report safety data on Avandia.

A sentence written by a marketer carries the same legal weight in this sector as a sentence written by a medical director. Before you draft copy you need three answers: which authority governs this product, which document defines the outer edge of what may be said about it, and whether the audience you want to reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → is permitted to hear it at all.

Four rule sets cover most of what a biotech or medtech marketer touches: the FDA and the FTC in the United States, EU medicines law (products often authorised centrally through the EMA, but advertising policed nationally), and the EU Medical Device Regulation.

The core principle: your claim must match your approval

Every regime here rests on one idea. A regulator authorised a specific product, for a specific use, in a specific population, at a specific dose, on the strength of a specific evidence package. Promotion lives inside that authorisation and nowhere else.

The authorisation is written down, and that document is where the work starts:

• In the US, the Prescribing Information approved with the drug. For a device, the cleared or approved indications for use.
• In the EU, the Summary of Product Characteristics (SmPC) annexed to the marketing authorisation. Article 87(2) of Directive 2001/83/EC requires every part of an advertisement to comply with it. For a device, the intended purpose recorded in the CE technical documentation.

Two terms you will use every week:

• On-label: the use, population and dose the regulator authorised. Promotable.
• Off-label: anything outside it. A physician may lawfully prescribe off-label; a company may not lawfully promote off-label. That asymmetry produces most of the enforcement in this sector, the GSK settlement included.

A third definition sets the scope of everything else. EU law defines advertising broadly (Article 86 of Directive 2001/83/EC): any information, canvassing activity or inducement designed to promote prescription, supply, sale or consumption, including representative visits, sponsorship of promotional meetings and gifts. A congress booth, a webinar and a paid social post are all promotion. Scientific exchange, answers to unsolicited medical enquiries and financial reporting to investors sit outside it, which is why most companies keep medical affairs and commercial in separate reporting lines.

FDA: the US gatekeeper for drugs and devices

The FDA (Food and Drug Administration) regulates prescription drug and medical device promotion in the United States. Drug advertising is reviewed by OPDP (Office of Prescription Drug Promotion).

The governing standard: promotional material must be truthful, not misleading, and fairly balanced. Fair balance means the risks get comparable prominence to the benefits, in the same piece, not in a footnote.

What that looks like in practice:

• A DTC (direct-to-consumer) TV ad for a prescription drug must carry the major risks (the "major statement") and a route to full prescribing information. The US is one of only two countries that permit prescription drug DTC advertising at all; the other is New Zealand.
• A post that states a benefit but has no room for risk is a classic violation. The FDA issued draft guidance on character-limited platforms in 2014.
• A device cleared only for diagnosis cannot be marketed as if it also treats the condition.

When the agency sees a problem it issues an Untitled Letter (a nudge) or a Warning Letter (serious). Both are public. The FDA Warning Letters database is the cheapest education available on where the line sits.

One case complicates the picture, and you should know it before someone in a launch meeting cites it badly. In 2015 Amarin sued the FDA over Vascepa, seeking to give physicians truthful data from a completed trial in patients with persistently high triglycerides on statin therapy, an indication the agency had declined. The Southern District of New York held that the First Amendment protects truthful, non-misleading speech about a lawful off-label use, and the FDA settled the following year. Read the limits carefully: "truthful and non-misleading" carries the entire ruling, it arose from specific statements Amarin submitted to the court, and it does not turn off-label into a promotable indication.

Two device pathways that change your claims

• 510(k) clearance: the device is "substantially equivalent" to a legally marketed predicate. You may claim only what that equivalence supports, and you write "FDA cleared."
• PMA (Premarket Approval): the high-risk pathway, for example implantable devices. Here "FDA approved" is accurate.

Getting the verb wrong is a real compliance error, and it is the one an outside reviewer spots first.

FTC: the consumer-protection layer

The FTC (Federal Trade Commission) polices advertising for health products the FDA does not tightly control, and shares ground with it elsewhere. Under a 1971 working agreement between the two agencies, the FTC takes primary responsibility for advertising of over-the-counter products while the FDA keeps labelling and prescription drug promotion. In practice the FTC is your rulebook for:

• Dietary supplements and wellness products
• OTC products, alongside the FDA
• Health apps and consumer wearables that are not regulated devices

The standard is competent and reliable scientific evidence. For a health claim that usually means well-designed human studies, not testimonials, and not a mechanism-of-action argument.

The FTC also enforces disclosure of paid relationships. If a company gifts or pays an influencer to talk about a wellness product, the connection must be clear in the post itself. The current standard sits in the FTC Endorsement Guides.

EMA and national agencies: the European drug picture

The EMA (European Medicines Agency) runs the centralised procedure, giving one marketing authorisation valid across the EU, and publishes the assessment behind it. It does not police your advertising. Enforcement happens at national level, under each member state's transposition of Directive 2001/83/EC, by agencies such as BfArM in Germany or the MHRA for the UK's separate post-Brexit regime, with industry self-regulatory bodies handling complaints in parallel.

What changes versus the US:

• Prescription medicines may not be advertised to the public. Article 88 of the Directive bans it. You may promote to healthcare professionals only. This single rule redraws the channel plan.
• OTC medicines may be advertised to the public, under tight content rules.
• Unbranded disease awareness communication is possible in most member states, but the conditions are strict and naming the product usually converts it into unlawful advertising.
• Codes from EFPIA and national associations add obligations on top of the law, and enforcement of those codes is a subject of its own.

The same asset library therefore splits early. A patient-facing campaign that is lawful in the US is unlawful in Germany, and a website reachable from both is a jurisdictional problem you solve with gating, not with a disclaimer.

EU MDR: the device rulebook in Europe

The MDR (Medical Device Regulation, EU 2017/745), applicable since 26 May 2021, governs devices in the EU and replaced the older Medical Device Directive.

The provision that constrains marketers is Article 7. You may not use text, names, trade names, pictures or figurative signs that:

• mislead the user about the device's intended purpose, safety or performance
• suggest uses the device is not certified for
• create a false impressionimpressionThe total number of times an ad or piece of content is displayed, regardless of clicks. Each display counts as one impression, even to the same person.View full definition → about treatment or diagnosis
• fail to inform the user of likely risks

A device on the EU market carries a CE mark, and your claims must stay inside its certified intended purpose. Advertising devices to the public is generally permitted, unlike prescription medicines, which is why the same company can run consumer campaigns for its device and professional-only campaigns for its drug in one country.

A practical decision mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.View full definition →

Before writing a claim, answer in this order:

1. Is this communication promotional at all? Scientific exchange and investor material follow different rules and different owners.
2. What is the product? Drug, device, supplement or app. This picks the primary regulator.
3. What geography? US (FDA, FTC) or EU (national authorities under EU medicines law, MDR for devices), and remember that a public website reaches both.
4. Who is the audience? Patients or healthcare professionals. In the EU, prescription DTC is banned outright.
5. Is the claim inside the label, SmPC or intended purpose? If it goes beyond, stop.

🎬 [VIDEO: "FDA Regulation of Prescription Drug Advertising" - youtube.com - clear overview of how OPDP reviews DTC and professional promotion]

Worked example: one product, two continents

Take a continuous glucose monitor (a wearable that tracks blood sugar), 510(kkThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition →) cleared in the US and CE marked in the EU.

US plan:

• Regulator: FDA, device centre rather than OPDP.
• Verb check: "FDA cleared", never "FDA approved".
• Audience: patients and clinicians both reachable.
• Channel: DTC digital advertising permitted, with risk information.
• Boundary: the cleared indications for use. No claim that it "prevents diabetes complications" unless the clearance supports it.

EU plan:

• Regulator: national competent authorities under MDR; CE mark in force.
• Article 7 check: nothing that overstates performance or implies an uncertified use.
• Audience: patient advertising allowed for devices, subject to national rules.
• Boundary: performance claims must match the technical documentation assessed for CE marking.

Same hardware, two boundary documents, two permitted vocabularies.

What the map decides before a campaign starts

Mapping is not paperwork for its own sake. It settles decisions that are expensive to reverse late:

• Which boundary document each claim will be traced back to, per market.
• Whether an asset can be one global master or must be built as separate market versions from the start.
• Which audiences are addressable at all, which determines the media budget split before a single line of copy exists.
• Who owns the answer when a claim sits between promotion and scientific exchange.
• How a public website, congress stand or LinkedIn account handles readers in jurisdictions where the product is not authorised.

The sign-off sequence that runs on top of this map, and the evidence file that supports each individual claim, are separate disciplines with their own owners.

Key Takeaways

• Match every claim to the authorisation. On-label is promotable; off-label promotion produced the GSK $3 billion settlement and most of the sector's enforcement history.
• Know your boundary document. US Prescribing Information or indications for use; EU SmPC or certified intended purpose. Every claim traces to one of them.
• Product plus geography plus audience picks your regulator. FDA and FTC in the US; national agencies under EU medicines law, plus MDR for devices, in Europe.
• The US allows prescription DTC advertising; the EU bans it. That single rule forces different channel strategies per market.
• Get the verb right: "FDA cleared" (510(k)) is not "FDA approved" (PMA).
• Study real FDA Warning Letters to see where peers crossed the line.

This lesson is educational and not legal advice; consult qualified regulatory counsel for specific campaigns.